[{"address1": "2 Corporate Drive", "address2": "First Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 239 2030", "website": "https://www.sentibio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 48, "companyOfficers": [{"maxAge": 1, "name": "Dr. Timothy K. Lu M.D., Ph.D.", "age": 42, "title": "Co-Founder, CEO & Director", "yearBorn": 1982, "fiscalYear": 2024, "totalPay": 630788, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kanya  Rajangam M.D., Ph.D.", "age": 50, "title": "President, Head of Research & Development and Chief Medical Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 528545, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James J. Collins Ph.D.", "age": 57, "title": "Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 43875, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Wilson  Wong Ph.D.", "title": "Scientific Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert H. Cutler J.D.", "age": 56, "title": "Senior VP & Head of Legal Affairs", "yearBorn": 1968, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas P. Chung", "title": "Vice President of Strategic Finance & Corporate Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Dee Olomajeye Dragon", "title": "VP of People & Culture Strategy & Head of Administrative Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 4.02, "open": 4.0229, "dayLow": 4.0229, "dayHigh": 4.36, "regularMarketPreviousClose": 4.02, "regularMarketOpen": 4.0229, "regularMarketDayLow": 4.0229, "regularMarketDayHigh": 4.36, "beta": 2.474, "forwardPE": -2.319149, "volume": 37703, "regularMarketVolume": 37703, "averageVolume": 2466305, "averageVolume10days": 24640, "averageDailyVolume10Day": 24640, "bid": 3.12, "ask": 5.38, "bidSize": 200, "askSize": 200, "marketCap": 21056446, "fiftyTwoWeekLow": 1.52, "fiftyTwoWeekHigh": 16.94, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 4.6498, "twoHundredDayAverage": 3.17465, "currency": "USD", "enterpriseValue": 43879492, "floatShares": 3107201, "sharesOutstanding": 4829460, "sharesShort": 103785, "sharesShortPriorMonth": 63574, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0215, "heldPercentInsiders": 0.16098, "heldPercentInstitutions": 0.19088, "shortRatio": 1.31, "shortPercentOfFloat": 0.0256, "impliedSharesOutstanding": 4829460, "bookValue": 3.487, "priceToBook": 1.2503585, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -70868000, "trailingEps": -15.59, "forwardEps": -0.75, "lastSplitFactor": "1:10", "lastSplitDate": 1721260800, "enterpriseToEbitda": -0.828, "52WeekChange": 0.004999995, "SandP52WeekChange": 0.22903383, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SNTI", "underlyingSymbol": "SNTI", "shortName": "Senti Biosciences, Inc.", "longName": "Senti Biosciences, Inc.", "firstTradeDateEpochUtc": 1622035800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "6e1c0497-dfb2-3427-8088-6f54c5e467cc", "messageBoardId": "finmb_538838857", "gmtOffSetMilliseconds": -18000000, "currentPrice": 4.36, "targetHighPrice": 12.0, "targetLowPrice": 12.0, "targetMeanPrice": 12.0, "targetMedianPrice": 12.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 10836000, "totalCashPerShare": 2.361, "ebitda": -52964000, "totalDebt": 34709000, "quickRatio": 1.326, "currentRatio": 1.918, "debtToEquity": 217.013, "returnOnAssets": -0.37507, "returnOnEquity": -1.43269, "grossProfits": -35706000, "freeCashflow": 2945375, "operatingCashflow": -34930000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]